Interpace Diagnostics Group, Inc.(NASDAQ : IDXG)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Loading IDXG News...
Health Services » Servicestothe Health Industry
|ESRX||Express Scripts Holding Company||-0.10%||61.34||5.7%||$378.25m|
|LH||Laboratory Corporation of America Holdings||0.34%||140.16||2.2%||$112.71m|
|DGX||Quest Diagnostics Incorporated||-0.20%||105.60||4.2%||$107.73m|
|Q||Quintiles Transnational Holdings, Inc.||0.73%||84.29||4.0%||$97.87m|
|INCR||INC Research Holdings, Inc. Class A||0.56%||45.00||6.5%||$69.23m|
|MDRX||Allscripts Healthcare Solutions, Inc.||-0.75%||11.97||9.3%||$21.46m|
|ABCO||Advisory Board Company||4.07%||51.10||6.2%||$19.64m|
|HCSG||Healthcare Services Group, Inc.||-1.35%||45.91||6.8%||$19.35m|
|AMRI||Albany Molecular Research, Inc.||-3.44%||16.01||15.6%||$15.95m|
|IDXG||Interpace Diagnostics Group, Inc.||-1.72%||2.28||13.7%||$9.60m|
Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.